Genprex, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Genprex, Inc. (GNPX) on August 4, 2026. The report addresses the status of the Company's listing on The Nasdaq Capital Market following a prior notification regarding compliance with the $1.00 Minimum Bid Price requirement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory listing status rather than financial performance.
Material Changes
On August 4, 2026, the Nasdaq Hearings Panel formally notified Genprex that the Company has regained compliance with the Nasdaq Listing Rule 5550(a)(2) Minimum Bid Price Requirement. This follows a previous request for an exception granted on July 29, 2026.
Outlook, Risks, and Contingencies
- Compliance Period: The Panel will maintain jurisdiction over the Company until December 7, 2026.
- Maintenance Requirement: The Company must maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026.
- Future Non-Compliance: If the Company becomes non-compliant with any other Listing Rule before December 7, 2026, it will have seven calendar days to advise the Panel of a cure plan. The Panel will then decide whether to grant an exception or delist the Company.
Investor Verification Checklist
- Verify the current daily closing bid price of GNPX to ensure it remains at or above $1.00.
- Monitor for any future 8-K filings indicating non-compliance with other Nasdaq Listing Rules prior to December 7, 2026.
- Confirm the Company's plan to maintain compliance if the stock price approaches the $1.00 threshold.